Prof. Dr. Reza Nejadnik's research at the University of Iowa, College of Pharmacy, is focused on protein pharmaceuticals, their formulation and characterization, and interaction of biologics with interfaces.
Genentech’s investigational, refillable eye implant—designed to deliver a new formulation of Lucentis' active ingredient, ranibizumab, continuously to wet age-related macular degeneration patients—showed positive results in a phase 2 trial compared to the